ANA is heartened by recent advances in the field of Alzheimer’s disease. We will be watching the upcoming FDA and Medicare submission closely and anticipate an eventual non-controversial approval of lecanemab. At that time, we hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease, and provide a clinically meaningful impact on cognition and function,” said Michel Vounatsos, Chief Executive Officer at Biogen.